Kamal Bouabdallah

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Olivier Hermine, Eva Hoster, Jan Walewski et al. · The Lancet · 2016 · 401 citations

Medicine, Immunology, Oncology +17

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Franck Morschhauser, Nathan Fowler, Pierre Feugier et al. · New England Journal of Medicine · 2018 · 362 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

Laurie H. Sehn, Neil Chua, Marek Trněný et al. · The Lancet Oncology · 2016 · 343 citations

Medicine, Oncology, Pharmacology +13

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Philippe Armand, Scott J. Rodig, Catherine Thiéblemont et al. · Journal of Clinical Oncology · 2019 · 259 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

Bruce D. Cheson, Neil Chua, Greg Dueck et al. · Journal of Clinical Oncology · 2018 · 167 citations · Full text

Medicine, Oncology, Pharmacotherapy +14